MedTrace Logo

Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

NCT02975115 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2016-11-29

No results posted yet for this study

Summary

This study is designed to confirm the efficacy of dasatinib 100mg once daily in producing a complete molecular response and to prove a possibility of "Operational Cure" in CMR patients.

Conditions

  • Chronic Myelocytic Leukemia

Interventions

OTHER

RQ-PCR RNA Analysis

Conventional Q-RT-PCR every 3 months

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-11-30
Completion
2018-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975115 on ClinicalTrials.gov